(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Acurx Pharmaceuticals's earnings in 2025 is -$11,874,407.On average, 1 Wall Street analyst forecast ACXP's earnings for 2025 to be -$10,566,723, with the lowest ACXP earnings forecast at -$10,566,723, and the highest ACXP earnings forecast at -$10,566,723. On average, 1 Wall Street analyst forecast ACXP's earnings for 2026 to be -$9,157,826, with the lowest ACXP earnings forecast at -$9,157,826, and the highest ACXP earnings forecast at -$9,157,826.
In 2027, ACXP is forecast to generate -$8,218,562 in earnings, with the lowest earnings forecast at -$8,218,562 and the highest earnings forecast at -$8,218,562.